We next tested the cytotoxic activity of VIP152 in 10 treatment-naïve primary CLL samples and 8 primary samples derived from patients who have relapsed or were refractory to BTK inhibitor therapy and venetoclax (Fig. 2K). Here, BTK is linked to B-cell chronic lymphocytic leukemia.